The clinical-stage company has a portfolio of innovative treatments, including a first-in-class monoclonal therapy for atopic dermatitis and other immunology indications, as well as a small molecule inhibitor targeting oncology. ASLAN is evaluating ASLAN004, a potential first-in-class antibody targeting the IL-13 receptor, in atopic dermatitis, and ASLAN003, a potent oral inhibitor of DHODH, which is being developed for autoimmune disease. The company has a team in Menlo Park, California, and in Singapore.